(Q37859364)

English

Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists

scientific article published on April 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1 reference

Europe PubMed Central

Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1

object named as

Paulina Deming

0 references

author name string

Paulina Deming

1

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Ian R McNicholl

2

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

language of work or name

0 references

publication date

1 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

357-368

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Hepatitis C and progression of HIV disease

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Viral hepatitis and HIV coinfection

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Therapeutical aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Side effects of therapy of hepatitis C and their management

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Boceprevir, an NS3 protease inhibitor of HCV.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

PEG IFN alfa-2a vs. alfa-2b: And the winner is …?

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.357

21 January 2018

Identifiers

10.1592/PHCO.31.4.357

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37859364&oldid=1731454950"